Q-omics provides the consensus-scored MAGT1 profile across patient tissues and cancer cell-line models. MAGT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAGT1 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, MAGT1 protein abundance shows 26,667 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, THCA, and BRCA as cancer lineages where MAGT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGT1 survival associations across molecular data types. MAGT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGT1 RNA expression–survival associations across cancer types. High MAGT1 expression shows unfavorable associations in UVM, LGG, BRCA, PAAD and SCLC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAGT1 RNA expression.
This table summarizes MAGT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAGT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGT1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, KIRC and BRCA. The THCA box plot shows higher MAGT1 RNA expression in normal versus tumor tissue (log2 FC = −1.578, t-test p < 0.001).
This table shows molecular features associated with MAGT1 in patient tissues and cancer cell lines. In patient samples, MAGT1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
